Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1133 | DAXI for injection dose MEDIUM DOSE Wiki | 0.71 |
| drug1131 | DAXI for injection Dose HIGH DOSE Wiki | 0.71 |
| drug3682 | Spasticity Take Control Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009128 | Muscle Spasticity NIH | 1.00 |
| D009103 | Multiple Sclerosis NIH | 0.17 |
| D012598 | Scoliosi NIH | 0.16 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This study will examine the impacts of two different methods of managing MS-related spasticity of the lower limbs. Both interventions will be presented via video teleconference in group classes consisting of exercises to reduce spasticity.
Description: Impact of spasticity will be measured using the Multiple Sclerosis Spasticity Scale-88 at one month post intervention.
Measure: Impact of spasticity, measured by the Multiple Sclerosis Spasticity Scale-88 Time: One month post-interventionDescription: Severity of spasticity will be measured using the Numeric Rating Scale for Spasticity at one month post intervention.
Measure: Severity of spasticity, measured by the Numeric Rating Scale for Spasticity Time: One month post-interventionDescription: Fatigue will be measured using the Modified Fatigue Impact Scale at one month post intervention.
Measure: Fatigue, measured by the Modified Fatigue Impact Scale Time: One month post-interventionDescription: Sleep quality and quantity will be measured using Pittsburgh Sleep Quality Index at one month post intervention.
Measure: Sleep quality and quantity, measured by the Pittsburge Sleep Quality Index Time: One month post-interventionDescription: Impact on day-to-day life, measured by the Multiple Sclerosis Impact Scale-29 at one month post intervention.
Measure: Impact on day-to-day life, measured by the Multiple Sclerosis Impact Scale-29 Time: One month post-interventionDescription: Emotional Distress - Depression will be measured using PROMIS Item Bank v1.0 - Emotional Distress - Depression-Short Form 8a at one month post intervention.
Measure: PROMIS Item Bank v1.0 - Emotional Distress - Depression-Short Form 8a Time: One month post-interventionDescription: Impact on multiple sclerosis on walking, measured by the Multiple Sclerosis Walking Scale-12 at one month post intervention.
Measure: Impact on multiple sclerosis on walking, measured by the Multiple Sclerosis Walking Scale-12 Time: One month post-interventionDescription: Walking will be measured using the Timed 25 Foot Walk at one month post intervention, only if visit is in person.
Measure: Walking measured by the Timed 25 Foot Walk Time: One month post-interventionDescription: Walking and turning measured by the Timed Up and Go will be measured at one month post intervention, only if visit is in person.
Measure: Walking and turning measured by the Timed Up and Go Time: One month post-interventionDescription: Pain severity and interference measured by a modified version of the Brief Pain Inventory at one month post intervention.
Measure: Pain severity and interference Time: One month post interventionThis is a randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury. The study will be conducted in the U.S.A. , approximately 128 adult subjects from approximately 30 study centers will be randomly assigned (1:1:1:1) to one of four treatment groups. The study consists of a 21-day screening period, a treatment visit and follow-up visits.The study enrollment is discontinued early due to the impact of COVID-19 on enrollment.
Description: Mean change from baseline in muscle tone measured with the Modified Ashworth Scale (MAS) in the suprahypertonic muscle group (SMG) of the elbow, wrist, OR finger flexors at Week 6. Score range: 0 (Normal tone, no in tone) to 4 (Affected part{s} rigid in flexion or extension)
Measure: Change from Baseline from suprahypertonic muscle group (SMG) score Time: Week 6Description: Mean score on of the the Physician Global Impression of Change (PGIC) at Week 6. Score range: -4 (Markedly worse) to +4 (Markedly improved).
Measure: Change from Baseline Physician Global Impression of Change (PGIC) score Time: Week 6Description: Proportion of subjects who improve by a full point on the Modified Ashworth Scale (MAS) in the suprahypertonic muscle group (SMG). Score range: 0 (Normal tone, no increase in tone) to 4 (Affected part{s} rigid in flexion or extension)
Measure: Muscle tone improvement Time: Weeks 6 and 12Description: Proportion of subjects with improvement (score ≥ 1) on the Physician Global Impression of Change (PGIC). Score range: 0 (Normal tone, no increase in tone) to 4 (Affected part{s} rigid in flexion or extension)
Measure: Physician Global Impression of Change (PGIC) improvement Time: Weeks 6 and 12Description: Change in functional impairment as measured by the Disability Assessment Scale (DAS) for the principal treatment target (PTT). Score range: 0 (No disability) to 3 (Severe disability - normal activities limited).
Measure: Disability Assessment Scale (DAS) functional impairment Time: Weeks 6 and 12Description: Duration of effect
Measure: Duration of effect Time: Up to 36 weeksDescription: Number of subjects with potential Botulinum Toxin type A distant spread of toxin adverse events, and number of subjects who develop neutralizing antibodies to Botulinum Toxin Type A will be assessed.
Measure: Safety and immunogenicity assessment Time: Up to 36 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports